Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
galantamine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| galantamine 8 mg (ER) | ACTIVE_COMPARATOR | - |
| galantamine 16 mg (ER) | ACTIVE_COMPARATOR | - |
| BMS-708163 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| galantamine | DRUG | Capsule, Oral, 8 mg (ER), once daily, Days 1-7 |
| BMS-708163 | DRUG | Capsule, Oral, 125 mg, once daily, Days 15-24 |
Inclusion Criteria: * Healthy men and postmenopausal women Exclusion Criteria: * Gastrointestinal disorders * Bleeding disorders * Peptic ulcer disease * Cholecystectomy * Seizure disorder * Asthma * Chronic obstructive pulmonary disease * Urinary tract obstruction * Cardiac conduction abnormalit...
Top 20 of 24 competitors
Galantamine is a small molecule being studied for use in Alzheimer Disease. It is an investigational drug in clinical development, and it is not approved for this use. The drug has been evaluated in a Phase 1 clinical trial to assess its effects in patients with Alzheimer Disease.
Galantamine is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical research on this small molecule for the treatment of Alzheimer Disease. The drug is currently in Phase 1 of clinical development.
Galantamine is in Phase 1 of clinical development. It is an investigational drug being studied for Alzheimer Disease. The drug is not approved and remains in clinical trials. One Phase 1 study has been completed, and no active trials are currently listed for this asset.
Galantamine has been studied in one clinical trial, NCT01039194, titled "Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)." This Phase 1 study was completed in the United States and enrolled 18 participants with Alzheimer Disease.
No, galantamine is not the same as BMS-708163. In the clinical trial NCT01039194, galantamine extended release was studied as a substrate to evaluate the effect of BMS-708163 on its pharmacokinetics. The trial was designed to assess a potential drug-drug interaction between the two compounds.